Strength Seen in Furiex Pharmaceuticals (FURX): Stock Shoots 129.9% - Tale of the Tape

By Zacks Equity Research,

Shutterstock photo

Furiex Pharmaceuticals, Inc. ( FURX ) was a big mover last session, as the company saw its shares rise by nearly 130% on the day. The move came on solid volume too with far more shares changing hands than in a normal session after the company reported positive results from two late-stage studies of eluxadoline for patients suffering from diarrhea-predominant irritable bowel syndrome. The stock picked up sharply from the near-flat trend of $41.72 to $47.40 in the past one-month time frame.

This biopharmaceutical stock has seen no estimate revision over the past 7 days, while the Zacks Consensus Estimate remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Furiex currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Some better-ranked stocks in the same industry include DepoMed Inc. ( DEPO ), Endocyte, Inc. ( ECYT ) and Salix Pharmaceuticals Ltd. ( SLXP ). All these stocks carry a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

DEPOMED INC (DEPO): Get Free Report

ENDOCYTE INC (ECYT): Free Stock Analysis Report

FURIEX PHARMACT (FURX): Free Stock Analysis Report

SALIX PHARM-LTD (SLXP): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Investing Ideas , Stocks
Referenced Stocks: DEPO , ECYT , FURX , SLXP

More from


Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by